Coleen W. Hill

Associate

  • Coleen W. Hill
  • Phone: +1 215 979 1164

    Import to Address Book

  • Duane Morris LLP
    30 South 17th Street
    Philadelphia, PA 19103-4196
    USA
  • Duane Morris LLP
    1201 North Market St, Suite 501
    Wilmington, DE 19801
    USA

Coleen W. Hill is a trial attorney whose practice focuses on representing clients in the Life Sciences industry in complex commercial and regulatory disputes.  Ms. Hill has extensive experience litigating matters involving medical products regulated by the Food and Drug Administration (FDA) and the Federal Trade Commission, as well as issues arising under the Federal Food, Drug, and Cosmetic Act.        

Ms. Hill also advises companies on regulatory compliance issues and assists with responding to regulatory actions, including FDA Form 483s and Warning Letters.  She counsels pharmaceutical companies, biologics manufacturers, medical device companies, and cosmetic companies on complex issues arising under state and federal regulations.

Admitted to practice in both Pennsylvania and Delaware, Ms. Hill also litigates corporate governance disputes (including stockholder class and derivative litigation), statutory actions arising under Delaware corporate and alternative entity laws, and complex contractual disputes stemming from various corporate transactions.  In addition, Ms. Hill represents clients and employers in commercial and business tort disputes involving restrictive covenants, trade secrets, and unfair competition. 

Ms. Hill holds a leadership role in Duane Morris’s Life Sciences and Medical Technologies industry group and actively monitors, publishes, and presents on developing FDA issues affecting Life Sciences industry clients.  She is a member of the Food and Drug Law Institute’s 2025 Food and Drug Law Journal Advisory Board.  

Ms. Hill serves on the attorney Recruitment and Retention Committee for Duane Morris’s Philadelphia office.  She is a 2016 cum laude graduate of Villanova University School of Law, where she was managing editor of production for the Villanova Law Review, and a summa cum laude graduate of Southern Illinois University. 

Admissions

  • Pennsylvania
  • Delaware
  • U.S. District Court for the Eastern District of Pennsylvania
  • U.S. District Court for the District of Delaware

Education

  • Villanova University Charles Widger School of Law, J.D., cum laude, 2016
    - Managing Editor of Production, Villanova Law Review
  • Southern Illinois University, B.A., summa cum laude, 2013

Experience

  • Duane Morris LLP
    - Associate, 2020-present
  • Morris, Nichols, Arsht & Tunnell LLP
    - Associate, 2016-2020

Honors and Awards

  • Litigator of the Week Runner-Up, AmLaw Litigation Daily, December 13, 2024

Professional Activities

  • Food and Drug Law Institute
    - 2025 Food and Drug Law Journal Advisory Board

Representative Matters

  • Glass, et al. v. B. Braun Medical Inc., et al., Case No. 210500315 (Philadelphia Cty., Pa Dec. 5, 2024). Obtained a defense verdict on behalf of B. Braun, an international medical technology company, after a five-week trial in the Philadelphia Court of Common Pleas. Plaintiff sought damages, including punitive damages, on counts of negligence, gross negligence, willful and wanton misconduct, strict liability, and civil conspiracy, claiming her husband developed leukemia from exposure to ethylene oxide allegedly emitted from B. Braun’s facility in Allentown, Pennsylvania. The jury found B. Braun not liable on all counts.

  • Listrak Inc. v. DiClemente, et al., No. CI-24-03536 (Lancaster Cty., Pa Aug. 28, 2024). Obtained a consent injunction order on behalf of Listrak against one of its former senior sales leaders and her new employer in a non-compete and misappropriation of trade secrets action.

  • Represented the Stockholders’ Representatives of a pharmaceutical company seeking more than $200 million in damages related to the acquiring company’s failure to pay a “milestone” payment related to FDA approval of a biological drug.

  • NSM Insurance Group v. Nasman, et al., Case No. 2022-06310 (Montgomery Cty., Pa. May 20, 2022). Obtained a denial of a motion for a temporary restraining order filed by the plaintiff against its former underwriter and his new employer in a non-compete action.

  • In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation (MDL No. 2875). Represented a generic active pharmaceutical ingredient manufacturer, finished dose manufacturer, distributor, and retailers in the more than 1000 products liability and 18 consumer class fraud class actions that alleged bodily injury and economic loss claims arising out of an alleged nitrosamine “contaminant” in valsartan.

  • ECBM LP v. Brian M. Chance, Civ. Action No. 20-0830 (E.D. Pa. Oct. 15, 2020). Secured denial of motion for a preliminary injunction on behalf of former ECBM employee who joined Stephens Insurance, finding that ECBM failed to establish that it had more than a negligible likelihood of success on the merits of its claims in a non-compete and misappropriation of trade secrets action.

Selected Publications

Selected Speaking Engagements

  • Speaker, "When Things Go Wrong: Navigating Enforcement When the FDA, SEC, and DOJ Are All Involved," MassMEDIC Regulatory Roundup, November 15, 2023
  • Moderator, “Business and Legal Trends Impacting Emerging Technologies: How to Protect IP in an Increasingly Challenging Legal Environment,” Duane Morris Life Sciences GC Bootcamp Series, May 23, 2023
  • Speaker, "Recent Developments on the 'Fraud on the FDA' Theory of False Claim Liability," MassMEDIC Regulatory Roundup Event, Webinar, February 16, 2023
  • Speaker, "When Innovation Outpaces Regulation," MassMEDIC Annual Conference, December 6, 2022